Arbutus Biopharma Corp (ABUS) - Total Liabilities
Based on the latest financial reports, Arbutus Biopharma Corp (ABUS) has total liabilities worth $16.99 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Arbutus Biopharma Corp - Total Liabilities Trend (1998–2025)
This chart illustrates how Arbutus Biopharma Corp's total liabilities have evolved over time, based on quarterly financial data. See Arbutus Biopharma Corp (ABUS) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Arbutus Biopharma Corp Competitors by Total Liabilities
The table below lists competitors of Arbutus Biopharma Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Delta Israel Brands Ltd
TA:DLTI
|
Israel | ILA896.54 Million |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥1.22 Billion |
|
Ultra Jaya Milk Industry Tbk
JK:ULTJ
|
Indonesia | Rp1.18 Trillion |
|
Pearl Global Industries Limited
NSE:PGIL
|
India | Rs18.07 Billion |
|
Apacer Technology Inc
TW:8271
|
Taiwan | NT$2.55 Billion |
|
Shenzhen Sea Star Technology
SHE:002137
|
China | CN¥336.29 Million |
|
STEVANATO GROUP SPA O.N.
F:87N
|
Germany | €1.05 Billion |
|
Apotea
ST:APOTEA
|
Sweden | Skr1.28 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down Arbutus Biopharma Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ABUS stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 54.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arbutus Biopharma Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arbutus Biopharma Corp (1998–2025)
The table below shows the annual total liabilities of Arbutus Biopharma Corp from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $18.04 Million | -47.46% |
| 2024-12-31 | $34.34 Million | -10.53% |
| 2023-12-31 | $38.38 Million | -34.46% |
| 2022-12-31 | $58.57 Million | +67.11% |
| 2021-12-31 | $35.05 Million | -0.19% |
| 2020-12-31 | $35.11 Million | +7.08% |
| 2019-12-31 | $32.79 Million | +18.50% |
| 2018-12-31 | $27.67 Million | -49.41% |
| 2017-12-31 | $54.70 Million | -24.97% |
| 2016-12-31 | $72.90 Million | -55.71% |
| 2015-12-31 | $164.61 Million | +445.07% |
| 2014-12-31 | $30.20 Million | +141.17% |
| 2013-12-31 | $12.52 Million | +7.24% |
| 2012-12-31 | $11.68 Million | +37.42% |
| 2011-12-31 | $8.50 Million | -17.40% |
| 2010-12-31 | $10.29 Million | +58.04% |
| 2009-12-31 | $6.51 Million | +60.61% |
| 2008-12-31 | $4.05 Million | -37.30% |
| 2007-12-31 | $6.46 Million | +9.95% |
| 2006-12-31 | $5.88 Million | -84.11% |
| 2005-12-31 | $36.99 Million | -28.31% |
| 2004-12-31 | $51.60 Million | +602.22% |
| 2003-12-31 | $7.35 Million | -6.62% |
| 2002-12-31 | $7.87 Million | +28.60% |
| 2001-12-31 | $6.12 Million | +145.24% |
| 2000-12-31 | $2.49 Million | +29.89% |
| 1999-12-31 | $1.92 Million | +36.71% |
| 1998-12-31 | $1.40 Million | -- |
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and A… Read more